Literature DB >> 14744030

Enhanced uptake of a heterologous protein with an HIV-1 Tat protein transduction domains (PTD) at both termini.

Jiyoon Ryu1, Kyuhyung Han, Jinseu Park, Soo Young Choi.   

Abstract

Poor membrane permeability of proteins is a major limitation of protein therapy. In a previous study, we showed that the minimal sequence required for efficient transduction of Tat-GFP is the basic domain from 49-57 of HIV-1 Tat called the protein transduction domain (PTD. Here we have generated HIV-1 Tat PTD GFP fusion proteins in which HIV-1 Tat PTD is fused with the N- and/or C-termini of GFP. The various GFP fusion proteins were purified from Escherichia coli and characterized for their ability to enter mammalian cells using Western blot analysis, confocal microscopy and flow cytometry. The GFP fusion protein with Tat PTD at its C-terminus was taken up as efficiently as the GFP fusion protein with Tat PTD at its N-terminus. However, the same protein with PTDs at its both termini was taken up even more efficiently. All the GFP fusion proteins were present in both the nucleus and cytosol of the transduced cells. Uptake was lower at 4 degrees C than at 37 degrees C. The availability of the expression vectors developed in this study may help to devise novel strategies in the rational development of protein-based drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14744030

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  4 in total

1.  TAT-mediated intracellular protein delivery to primary brain cells is dependent on glycosaminoglycan expression.

Authors:  Melissa J Simon; Shan Gao; Woo Hyeun Kang; Scott Banta; Barclay Morrison
Journal:  Biotechnol Bioeng       Date:  2009-09-01       Impact factor: 4.530

2.  Relevance of biophysical interactions of nanoparticles with a model membrane in predicting cellular uptake: study with TAT peptide-conjugated nanoparticles.

Authors:  Chiranjeevi Peetla; Kavitha S Rao; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

3.  Delivery of HSF1(+) protein using HIV-1 TAT protein transduction domain.

Authors:  Yonghui Hou; Jiangying Zou
Journal:  Mol Biol Rep       Date:  2009-02-04       Impact factor: 2.316

4.  Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.

Authors:  Byoung-Shik Shim; In Su Cheon; Eugene Lee; Sung-Moo Park; Youngjoo Choi; Dae-Im Jung; Eunji Yang; Jung-Ah Choi; June Young Chun; Jae-Ouk Kim; Cheol-Heui Yun; Cecil Czerkinsky; Man Ki Song
Journal:  J Immunol Res       Date:  2018-03-07       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.